Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05246670 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Feb 28, 2025 to Feb 28, 2026v27
  2. Results first posted: Jan 24, 2025v26
  3. Primary endpoint revised
    • Primary completion date changed from estimate of Aug 31, 2024 to Feb 12, 2024
    • Secondary endpoints revised (2)
    v25
  4. Re-verified, no change to tracked fieldsv24
  5. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 15 to 10
    v23
Show 21 earlier versionsHide 21 earlier versions
  1. Study sites: 13 to 15
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study description expanded, about 116 words
    • Eligibility criteria expanded, about 5 words
    v22
  2. Primary completion date: Apr 30, 2024 to Aug 31, 2024v21
  3. Site details revised at 1 of 13 sitesv20
  4. Site details revised at 1 of 13 sitesv19
  5. Primary completion date: Aug 31, 2023 to Apr 30, 2024
    • Study completion date: Jun 30, 2024 to Feb 28, 2025
    v18
  6. Site details revised at 1 of 13 sitesv17
  7. Site details revised at 1 of 13 sitesv16
  8. Site details revised at 1 of 13 sitesv15
  9. Site details revised at 1 of 13 sitesv14
  10. Site details revised at 2 of 13 sitesv13
  11. Start date changed from estimate of Nov 16, 2022 to May 16, 2022
    • Site details revised at 1 of 13 sites
    v12
  12. Site details revised at 1 of 13 sitesv11
  13. Site details revised at 1 of 13 sitesv10
  14. Study sites: 12 to 13v9
  15. Site contacts updated at 1 of 12 sitesv8
  16. Study sites: 9 to 12v7
  17. Start date: Jul 16, 2022 to Nov 16, 2022v6
  18. Start date: May 16, 2022 to Jul 16, 2022v5
  19. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 1, 2022 to May 16, 2022
    • Site details revised at 9 of 9 sites
    v4
  20. Start date: Mar 31, 2022 to Jun 1, 2022
    • Study title shortened, about 9 words
    v3
  21. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests whether PEA works to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer. Chemotherapy-induced peripheral neuropathy refers to a nerve problem that causes pain, numbness, tingling, or muscle weakness in different parts of the body, and is caused by chemotherapy. PEA may be useful against bothersome nerve symptoms.
Trial Details
NCT Number NCT05246670
Lead Sponsor Academic and Community Cancer Research United
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Related terms Hematologic Neoplasms
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov